Boehringer loses India patent to Cipla

revoke-power-of-attorney

(Photo Courtesy: www.thekansascitylawyer.com)

In a landmark decision, India's patent office has revoked the patent of German-based pharmaceutical giant Boehringer Ingelheim's chronic obstructive pulmonary disease drug Spiriva (tiotropium).

Back in 2012, Boehringer received its Indian patent on Spiriva, which extended up to 2021.

In 2013, Cipla filed its patent opposition saying the drug didn't constitute invention under India's patent laws.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email

X